Clarification of the role of the Jaydess(Skyla) LNG- IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems.

Jaydess/Skyla and Kyleena are 'low dose' levonorgestrel releasing intrauterine systems(LNG-IUS). They differ from Mirena and other similar LNG-IUSs in terms of pharmacological properties and physical dimensions. There are currently no defined guidelines to decide when to use Jaydess or Kyleena or Mirena. Areas covered: MEDLINE, POPLINE, PubMed and clinicaltrials.gov were searched using the terms 'Jaydess', 'Skyla', LNG-IUS 13.5mg and 'Kyleena' LNG-IUS 19.5mg. Only clinical research articles as opposed to generalised reviews and opinion papers on the newer LNG-IUSs were considered for review. There were 10 clinical research articles and 11 clinical research abstracts relating to Jaydess/Skyla(LNG-IUS13.5mg) and Kyleena(LNG-IUS 19.5mg). All the studies were sponsored by the manufacturer. There were no independent clinical research studies. Expert commentary: The clinical research information from studies on Jaydess/Skyla and Kyleena does not adequately inform the clinician when and where these IUSs should be used in preference to other LNG-containing IUSs. The terminology used for describing the new low dose LNG-IUSs is inconsistent. The clinical differences between Jaydess, Kyleena and Mirena and the clinical differences in parity of subjects using Jaydess or Kyleena is used to generate an algorithm for helping clinicians choose between Mirena and Jaydess/Skyla or Kyleena.